Literature DB >> 31646284

Is diabetes mellitus equivalent to atherosclerotic cardiovascular disease from a healthcare cost perspective? Insights from the Medical Expenditure Panel Survey: 2010-2013.

David I Feldman1,2, Javier Valero-Elizondo3,4, Joseph A Salami3, Jamal S Rana5, Oluseye Ogunmoroti3, Victor Okunrintemi3, Chukwuemeka U Osondu3, Erica S Spatz6, Salim S Virani7, Ron Blankstein8, Michael J Blaha2, Emir Veledar3, Khurram Nasir3,2,6.   

Abstract

Diabetes mellitus (DM) and atherosclerotic cardiovascular disease (ASCVD) both increase the risk for a major adverse cardiac event, and are therefore considered priority conditions clinically. Although guidelines encourage clinicians to treat them similarly, many researchers do not consider DM an ASCVD risk-equivalent. However, from a healthcare system standpoint it is more important to determine whether DM is an economic burden equivalent to ASCVD. Using data from the Household Component of the 2010-2013 Medical Expenditure Panel Survey, we determined that the diagnosis of DM yields significantly lower healthcare expenditures and resource utilization when compared with ASCVD. In fact, the healthcare cost associated with DM alone is almost $1000 less than ASCVD. That being said, the cost and resource utilization was highest among those individuals diagnosed with ASCVD+DM, underscoring the importance of primary and secondary prevention to help detect individuals early and initiate proper lifestyle and aggressive therapeutic managements.
Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Keywords:  atherosclerotic cardiovascular disease; cardiovascular prevention; cost-effectiveness; diabetes mellitus

Year:  2018        PMID: 31646284      PMCID: PMC6739895          DOI: 10.1097/XCE.0000000000000151

Source DB:  PubMed          Journal:  Cardiovasc Endocrinol Metab        ISSN: 2574-0954


  5 in total

1.  Diabetes and coronary risk equivalency: what does it mean?

Authors:  Scott M Grundy
Journal:  Diabetes Care       Date:  2006-02       Impact factor: 19.112

2.  Trends in lifetime risk and years of life lost due to diabetes in the USA, 1985-2011: a modelling study.

Authors:  Edward W Gregg; Xiaohui Zhuo; Yiling J Cheng; Ann L Albright; K M Venkat Narayan; Theodore J Thompson
Journal:  Lancet Diabetes Endocrinol       Date:  2014-08-12       Impact factor: 32.069

3.  Favorable Cardiovascular Risk Profile Is Associated With Lower Healthcare Costs and Resource Utilization: The 2012 Medical Expenditure Panel Survey.

Authors:  Javier Valero-Elizondo; Joseph A Salami; Oluseye Ogunmoroti; Chukwuemeka U Osondu; Ehimen C Aneni; Rehan Malik; Erica S Spatz; Jamal S Rana; Salim S Virani; Ron Blankstein; Michael J Blaha; Emir Veledar; Khurram Nasir
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2016-03-03

4.  Diabetes and Prior Coronary Heart Disease are Not Necessarily Risk Equivalent for Future Coronary Heart Disease Events.

Authors:  Jamal S Rana; Jennifer Y Liu; Howard H Moffet; Marc Jaffe; Andrew J Karter
Journal:  J Gen Intern Med       Date:  2015-12-14       Impact factor: 5.128

5.  Costs of Chronic Diseases at the State Level: The Chronic Disease Cost Calculator.

Authors:  Justin G Trogdon; Louise B Murphy; Olga A Khavjou; Rui Li; Christopher M Maylahn; Florence K Tangka; Tursynbek A Nurmagambetov; Donatus U Ekwueme; Isaac Nwaise; Daniel P Chapman; Diane Orenstein
Journal:  Prev Chronic Dis       Date:  2015-09-03       Impact factor: 2.830

  5 in total
  1 in total

1.  Cumulative Burden of Financial Hardship From Medical Bills Across the Spectrum of Diabetes Mellitus and Atherosclerotic Cardiovascular Disease Among Non-Elderly Adults in the United States.

Authors:  Reed Mszar; Gowtham R Grandhi; Javier Valero-Elizondo; César Caraballo; Rohan Khera; Nihar Desai; Salim S Virani; Ron Blankstein; Michael J Blaha; Khurram Nasir
Journal:  J Am Heart Assoc       Date:  2020-05-12       Impact factor: 5.501

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.